Assessment and management of vascular implant thrombogenecity

Thrombus and Stroke

Volumn , Issue , 2008, Pages 57-78

  Sukavaneshvar, Sivaprasad ^a  

^a Medical Device Evaluation Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902230580     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (79)

1. Komotar RJ, Mocco J, Wilson DA, et al. Current endovascular treatment options for intracranial carotid artery atherosclerosis. Neurosurg Focus 2005; 18 (1): e5.
2. Andaluz N, Zuccarello M. Evidence-based surgical treatment of carotid stenosis. Literature review. J Neurosurg Sci 2004; 48 (1): 1-9.
3. Bendok BR, Hanel RA, Hopkins LN. Coil embolization of intracranial aneurysms. Neurosurgery 2003; 52 (5): 1125-1130; discussion 1130.
4. Sukavaneshvar S. In-vitro assessment of device thrombosis and thromboembolism. Proceedings of Roadmap to Successful Development and Regulatory Approval of Medical Devices with Hemocompatible Coatings Workshop, Surfaces in Biomaterials Foundation, Scottsdale, AZ, Aug 2001.
5. Sakariassen KS, Hanson SR, Cadroy Y. Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy. Thromb Res 2001; 104 (3): 149-174.
6. International Organization for Standardization. Guideline document for the assessment of blood contacting device hemocompatibility (ISO 10993-4).
7. Sukavaneshvar S, Solen KA, Mohammad SF. An in-vitro model to study device-induced thrombosis and embolism: evaluation of the efficacy of tirofiban, aspirin, and dipyridamole. Thromb Haemost 2000; 83 (2): 322-326.
8. Sukavaneshvar S, Rosa GM, Solen KA. Enhancement of stent-induced thromboembolism by residual stenoses: contribution of hemodynamics. Ann Biomed Eng 2000; 28 (2): 182-193.
9. Sukavaneshvar S, Solen KA, Mohammad SF. Device induced thromboembolism in a bovine in vitro coronary stent model. ASAIO J 1998; 44 (5): M393-M396.
10. Sukavaneshvar S, Solen KA. Effects of hemodynamics on thromboembolism in coronary stents and prototype flow cells in vitro. ASAIO J 1998; 44 (5): M388-M392.
11. Lane DA, Lindahll U. Heparin: Chemical and Biological Properties, Clinical Applications. Boca Raton, FL: CRC Press, 1989.
12. Sukavaneshvar S, Watts M, Bingham J, et al. Assessment of thromboresistance of surface coatings using a novel branched conduit blood flow model. Abstracts of Papers, p. 60, BioInterface 2004 Symposium, Surfaces in Biomaterials Foundation, Baltimore, MD, Oct 27-29, 2004.
13. Thakur ML, Welch MJ, Joist JH, et al. Indium-111 labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res 1976; 9 (4): 345-357.
14. Foo RS, Gershlick AH, Hogrefe K, et al. Inhibition of platelet thrombosis using an activated protein C-loaded stent: in vitro and in vivo results. Thromb Haemost 2000; 83 (3): 496-502.
15. Wabers HD, Hergenrother RW, Coury AJ, et al. Thrombus deposition on polyurethanes designed for biomedical applications. J Appl Biomater 1992; 3 (3): 167-176.
16. Solen K, Sukavaneshvar S, Zheng Y, et al. Light-scattering instrument to detect thromboemboli in blood. J Biomed Opt 2003; 8 (1): 70-79.
17. Reynolds LO, Simon T. Size distribution measurements in microaggregates in stored whole blood. Transfusion 1980; 20: 669-678.
18. Reynolds LO. Light scattering detection of microemboli. Transactions of the 11th Annual Meeting of the Society for Biomaterials and the 17th International Biomaterials Symposium, Society for Biomaterials, San Diego, CA, Apr 24-28, 1985; 8: 20.
19. Peng Y. Characterization of microemboli in whole blood by a new laser light-scattering technique (master’s thesis). Provo, UT: Brigham Young University, Department of Chemical Engineering, 1994.
20. Zheng Y, Mohammad S, Solen KA. The light-scattering whole blood aggregometer: a novel device for assessment of platelet aggregation in undiluted blood. Arch Pathol Lab Med 1998; 122: 880-886.
21. Sukavaneshvar S, Zheng Y, Rosa GM, et al. Thromboembolization associated with sudden increases in flow in a coronary stent ex vivo shunt model. ASAIO J 2000; 46 (3): 301-304.
22. Sukavaneshvar S, Mohammad F, Herce J, et al. The relative influence of polymer matrices on stent-induced thrombosis and embolism. Abstract#169: Transactions of the 6th World Biomaterials Congress, Kamuela, Hawaii, May 15-20, 2000.
23. Meola S, Burns G, Sukavaneshvar S, Solen K, Mohammad S. Mitigation of deviceassociated thrombosis and thromboembolism using combinations of heparin and tirofiban. J Extra Corpor Technol. 2006; 38 (3): 230-234.
24. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338 (21): 1488-1497.
25. Makkar RR, Eigler NL, Kaul S, et al. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J 1998; 19 (10): 1538-1546.
26. Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005; 3 (8): 1597-1602.
27. Knoepp SM, Laposata M. Aspirin resistance: moving forward with multiple definitions, different assays, and a clinical imperative. Am J Clin Pathol 2005; 123 (suppl): S125-S132.
28. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005; 45 (8): 1157-1164.
29. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol 2003; 41 (6): 966-968.
30. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105 (14): 1650-1655.
31. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88 (3): 230-235.
32. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41 (6): 961-965.
33. Ajani AE, Cheneau E, Leborgne L, et al. Have we solved the problem of late thrombosis? Minerva Cardioangiol 2002; 50 (5): 463-468.
34. Van Cott EM, Laposata M. Coagulation. In: Jacobs DS, DeMott WR, Oxley DK, eds. The Laboratory Test Handbook, 5th ed. Cleveland: Lexi-Comp, 2001: 327-358.
35. Ezekowitz MD. Anticoagulation management of valve replacement patients. J Heart Valve Dis 2002; 11 (suppl 1): S56-S60.
36. Nicholson NS, Panzer-Knodle SG, Haas NF, et al. Assessment of platelet function assays. Am Heart J 1998; 135 (5 Pt 2 Su): S170-S178.
37. Marcus AJ. Platelet aggregation. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
38. Born GVR. Platelets: functional physiology. In: Biggs R, ed. Human Blood Coagulation, Haemostasis and Thrombosis. London: Blackwell Scientific Publications, 1972.
39. Breddin HK. Can platelet aggregometry be standardized? Platelets 2005; 16 (3-4): 151-158.
40. Pongracz E. Measurement of platelet aggregation during antiplatelet therapy in ischemic stroke. Clin Hemorheol Microcirc 2004; 30 (3-4): 237-242.
41. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25 (12): 2331-2336.
42. Faraday N, Scharpf RB, Dodd-o JM, et al. Leukocytes can enhance platelet-mediated aggregation and thromboxane release via interaction of P-selectin glycoprotein ligand 1 with P-selectin. Anesthesiology 2001; 94 (1): 145-151.
43. Miller DD, Karim MA, Edwards WD, et al. Relationship of vascular thrombosis and inflammatory leukocyte infiltration to neointimal growth following porcine coronary artery stent placement. Atherosclerosis 1996; 124 (2): 145-155.
44. Barradas MA, Stansby G, Hamilton G, et al. Diminished platelet yield and enhanced platelet aggregability in platelet-rich plasma of peripheral vascular disease patients. Int Angiol 1994; 13 (3): 202-207.
45. Zwierzina WD, Kunz F. A method of testing platelet aggregation in native whole blood. Thromb Res 1985; 38 (1): 91-100.
46. Dyszkiewicz-Korpanty AM, Frenkel EP, Sarode R. Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods. Clin Appl Thromb Hemost 2005; 11 (1): 25-35.
47. Kundu SK, Heilmann EJ, Sio R, et al. Description of an in vitro platelet function analyzer— PFA-100. Semin Thromb Hemost 1995; 21 (suppl 2): 106-112.
48. von Pape KW, Strupp G, Bonzel T, et al. Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction. Thromb Haemost 2005; 94 (4): 889-891.
49. Golanski J, Chlopicki S, Golanski R, et al. Resistance to aspirin in patients after coronary artery bypass grafting is transient: impact on the monitoring of aspirin antiplatelet therapy. Ther Drug Monit 2005; 27 (4): 484-490.
50. Andersen K, Hurlen M, Arnesen H, et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002; 108 (1): 37-42.
51. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88 (3): 230-235.
52. Alberts MJ, Bergman DL, Molner E, et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35 (1): 175-178.
53. Steinhubl SR, Varanasi SJ, Goldberg L. Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 42 (7): 1336-1337. Letter to the Editor and Author Reply.
54. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999; 99 (5): 620-625.
55. Wheeler GL, Braden GA, Steinhubl SR, et al. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J 2002; 143 (4): 602-611.
56. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103 (21): 2572-2578.
57. Lee PY, Chen WH, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005; 118 (7): 723-727.
58. Serebruany VL, Malinin AI, Ziai W, et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. Stroke 2005; 36 (10): 2289-2292.
59. Harrison P, Segal H, Blasbery K, et al. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005; 36 (5): 1001-1005.
60. Malinin A, Spergling M, Muhlestein B, et al. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004; 15 (4): 295-301.
61. Wang JC, Aucoin-Barry D, Manuelian D, et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003; 92 (12): 1492-1494.
62. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43 (6): 1122-1126.
63. Salooja N, Perry DJ. Thrombelastography. Blood Coagul Fibrinolysis 2001; 12 (5): 327-337. Erratum in: Blood Coagul Fibrinolysis 2002; 13(1): 75.
64. Carroll RC, Craft RM, Chavez JJ, et al. A Thrombelastograph whole blood assay for clinical monitoring of NSAID-insensitive transcellular platelet activation by arachidonic acid. J Lab Clin Med 2005; 146 (1): 30-35.
65. Craft RM, Chavez JJ, Snider CC, et al. Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 2005; 145 (6): 309-315.
66. Chavez JJ, Foley DE, Snider CC, et al. A novel thrombelastograph tissue factor/kaolin assay of activated clotting times for monitoring heparin anticoagulation during cardiopulmonary bypass. Anesth Analg 2004; 99 (5): 1290-1294.
67. Shih RL, Cherng YG, Chao A, et al. Prediction of bleeding diathesis in patients undergoing cardiopulmonary bypass during cardiac surgery: viscoelastic measures versus routine coagulation test. Acta Anaesthesiol Sin 1997; 35 (3): 133-139.
68. Cherng YG, Chao A, Shih RL, et al. Preoperative evaluation and postoperative prediction of hemostatic function with thromboelastography in patients undergoing redo cardiac surgery. Acta Anaesthesiol Sin 1998; 36 (4): 179-186.
69. Martin P, Horkay F, Rajah SM, et al. Monitoring of coagulation status using thrombelastography during paediatric open heart surgery. Int J Clin Monit Comput 1991; 8 (3): 183-187.
70. Handa A, Platts A, Tone S, et al. Vascular surgical society of Great Britain and Ireland: thrombelastography can differentiate ischaemic from haemorrhagic stroke. Br J Surg 1999; 86 (5): 691.
71. Pavie A, Szefner J, Leger P, et al. Preventing, minimizing, and managing postoperative bleeding. Ann Thorac Surg 1999; 68: 705-710.
72. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46 (9): 1705-1709.
73. Tanaka KA, Szlam F, Kelly AB, et al. Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding. Platelets 2004; 15 (5): 325-332.
74. Carville DG, Schleckser PA, Guyer KE, et al. Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. J Extra Corpor Technol 1998; 30 (4): 171-177.
75. Lennon MJ, Gibbs NM, Weightman WM, et al. A comparison of Plateletworks and platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients. J Cardiothorac Vasc Anesth 2004; 18 (2): 136-140.
76. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109 (2): 166-171.
77. Ostrowsky J, Foes J, Warchol M, et al. Plateletworks platelet function test compared to the thromboelastograph for prediction of postoperative outcomes. J Extra Corpor Technol 2004; 36 (2): 149-152.
78. Zheng Y, Solen KA, Mohammad SF. The light-scattering whole blood aggregometer: a novel device for assessment of platelet aggregation in undiluted blood. Arch Pathol Lab Med 1998; 122 (10): 880-886.
79. Anderson J, Lappe J, Greene R, et al. Monitoring antiplatelet drug efficacy and resistance with a novel whole blood point-of-care platelet function analyzer. Abstract #615, Cardiovascular Revascularization Therapies, Washington, DC, Mar 2005.